novolimus
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Sep 30, 2020 (NCT04483791)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Mammalian target of Rapamycin (mTORC1)ANTAGONIST
Mammalian target of Rapamycin (mTORC1) antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04483791 | Phase 4 | Sep 30, 2020 | Elixir Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elixir Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1